NO986051D0 - Antikonvulsive derivater for behandling av manisk-depressive mangler - Google Patents
Antikonvulsive derivater for behandling av manisk-depressive manglerInfo
- Publication number
- NO986051D0 NO986051D0 NO986051A NO986051A NO986051D0 NO 986051 D0 NO986051 D0 NO 986051D0 NO 986051 A NO986051 A NO 986051A NO 986051 A NO986051 A NO 986051A NO 986051 D0 NO986051 D0 NO 986051D0
- Authority
- NO
- Norway
- Prior art keywords
- manic
- depressive
- deficiencies
- treatment
- anticonvulsant derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
- H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
- H04N21/43—Processing of content or additional data, e.g. demultiplexing additional data from a digital video stream; Elementary client operations, e.g. monitoring of home network or synchronising decoder's clock; Client middleware
- H04N21/442—Monitoring of processes or resources, e.g. detecting the failure of a recording device, monitoring the downstream bandwidth, the number of times a movie has been viewed, the storage space available from the internal hard disk
- H04N21/44213—Monitoring of end-user related data
- H04N21/44222—Analytics of user selections, e.g. selection of programs or purchase activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Social Psychology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Databases & Information Systems (AREA)
- Computer Networks & Wireless Communication (AREA)
- Multimedia (AREA)
- Signal Processing (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2085096P | 1996-06-28 | 1996-06-28 | |
US08/881,008 US5753693A (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
PCT/US1997/010949 WO1998000123A1 (en) | 1996-06-28 | 1997-06-24 | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
NO986051D0 true NO986051D0 (no) | 1998-12-22 |
NO986051L NO986051L (no) | 1999-02-23 |
NO317641B1 NO317641B1 (no) | 2004-11-29 |
Family
ID=26693960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19986051A NO317641B1 (no) | 1996-06-28 | 1998-12-22 | Anvendelsen av topiramat eller derivater derav for fremstilling av et medikament for behandling av manisk depressive, bipolare forstyrrelser |
Country Status (21)
Country | Link |
---|---|
US (1) | US5753693A (no) |
EP (1) | EP0932398B1 (no) |
JP (1) | JP2002515875A (no) |
KR (1) | KR20000022233A (no) |
CN (1) | CN1224350A (no) |
AP (1) | AP1401A (no) |
AT (1) | ATE330593T1 (no) |
AU (1) | AU739363B2 (no) |
BR (1) | BR9712783A (no) |
CA (1) | CA2258895C (no) |
CZ (1) | CZ297342B6 (no) |
DE (1) | DE69736183T2 (no) |
ES (1) | ES2267144T3 (no) |
HU (1) | HUP0003381A3 (no) |
IL (1) | IL127714A (no) |
NO (1) | NO317641B1 (no) |
NZ (1) | NZ333565A (no) |
RU (1) | RU2185824C2 (no) |
SK (1) | SK180498A3 (no) |
WO (1) | WO1998000123A1 (no) |
ZA (1) | ZA975773B (no) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6472370B1 (en) | 1998-11-17 | 2002-10-29 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating post traumatic stress disorder |
US20020006908A1 (en) * | 1998-12-03 | 2002-01-17 | Daniel P. Van Kammen | Anticonvulsant derivatives useful in treating schizophrenia |
ATE299371T1 (de) | 1999-02-08 | 2005-07-15 | Ortho Mcneil Pharm Inc | Antikonvulsiva zur behandlung von autismus |
ES2238999T3 (es) | 1999-02-24 | 2005-09-16 | University Of Cincinnati | Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos. |
MXPA01010217A (es) | 1999-04-08 | 2005-09-08 | Johnson & Johnson | Derivados anticonvulsivos utiles en el tratamiento de trastornos neurodegenerativos cronicos. |
US6420369B1 (en) | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
US7553818B2 (en) * | 1999-06-14 | 2009-06-30 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
DK1187603T3 (da) | 1999-06-14 | 2007-12-17 | Vivus Inc | Kombinationsterapi tl at bevirke vægttab og at behandle obesitet |
US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
US7659256B2 (en) * | 1999-06-14 | 2010-02-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US7056890B2 (en) | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
WO2002009694A1 (en) * | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
AU2002227052A1 (en) | 2000-11-30 | 2002-06-11 | University Of Florida | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
CA2459146A1 (en) * | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
US20040235957A1 (en) * | 2001-10-12 | 2004-11-25 | David Bleakman | Use of sulfonamide derivatives as pharmaceuticals compounds |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
US6559293B1 (en) * | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
US20030224006A1 (en) | 2002-03-01 | 2003-12-04 | Zaworotko Michael J. | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
EP1515703A1 (en) * | 2002-06-21 | 2005-03-23 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
US20050175697A1 (en) * | 2003-12-29 | 2005-08-11 | David Edgren | Novel drug compositions and dosage forms of topiramate |
US20040115262A1 (en) * | 2002-07-29 | 2004-06-17 | Frank Jao | Formulations and dosage forms for controlled delivery of topiramate |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US20050070524A1 (en) * | 2003-06-06 | 2005-03-31 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
MY147767A (en) * | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
AR049646A1 (es) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados |
JP4912312B2 (ja) * | 2004-08-24 | 2012-04-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗痙攣薬として有用な新規なベンゾ−縮合ヘテロアリールスルファミド誘導体 |
AU2006249577A1 (en) * | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
US8716231B2 (en) * | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8497298B2 (en) * | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8937096B2 (en) * | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
AR058389A1 (es) * | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
US20070191449A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression |
US20070191474A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
US20070191450A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder |
JP2009537635A (ja) * | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
ES2312308T3 (es) | 2006-11-17 | 2013-03-26 | Supernus Pharmaceuticals, Inc. | Formulaciones de liberación sostenida de topiramato |
AU2007329373B2 (en) | 2006-12-04 | 2013-06-20 | Supernus Pharmaceuticals, Inc. | Enhanced immediate release formulations of topiramate |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
CA2729056A1 (en) | 2008-06-23 | 2010-01-21 | Janssen Pharmaceutica Nv | Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8815939B2 (en) * | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US20220016074A1 (en) | 2018-11-21 | 2022-01-20 | Rosemont Pharmaceuticals Limited | Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
-
1997
- 1997-06-23 US US08/881,008 patent/US5753693A/en not_active Expired - Fee Related
- 1997-06-24 BR BR9712783-3A patent/BR9712783A/pt not_active Application Discontinuation
- 1997-06-24 ES ES97930212T patent/ES2267144T3/es not_active Expired - Lifetime
- 1997-06-24 AU AU34096/97A patent/AU739363B2/en not_active Ceased
- 1997-06-24 DE DE69736183T patent/DE69736183T2/de not_active Expired - Fee Related
- 1997-06-24 JP JP50424298A patent/JP2002515875A/ja not_active Ceased
- 1997-06-24 WO PCT/US1997/010949 patent/WO1998000123A1/en active IP Right Grant
- 1997-06-24 IL IL12771497A patent/IL127714A/en not_active IP Right Cessation
- 1997-06-24 CZ CZ0427798A patent/CZ297342B6/cs not_active IP Right Cessation
- 1997-06-24 HU HU0003381A patent/HUP0003381A3/hu unknown
- 1997-06-24 CN CN97195907A patent/CN1224350A/zh active Pending
- 1997-06-24 EP EP97930212A patent/EP0932398B1/en not_active Expired - Lifetime
- 1997-06-24 RU RU98123607/14A patent/RU2185824C2/ru not_active IP Right Cessation
- 1997-06-24 KR KR1019980710653A patent/KR20000022233A/ko not_active Application Discontinuation
- 1997-06-24 CA CA002258895A patent/CA2258895C/en not_active Expired - Fee Related
- 1997-06-24 AP APAP/P/1998/001427A patent/AP1401A/en active
- 1997-06-24 SK SK1804-98A patent/SK180498A3/sk unknown
- 1997-06-24 AT AT97930212T patent/ATE330593T1/de not_active IP Right Cessation
- 1997-06-24 NZ NZ333565A patent/NZ333565A/xx unknown
- 1997-06-27 ZA ZA975773A patent/ZA975773B/xx unknown
-
1998
- 1998-12-22 NO NO19986051A patent/NO317641B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
NO317641B1 (no) | 2004-11-29 |
HUP0003381A3 (en) | 2001-12-28 |
NO986051L (no) | 1999-02-23 |
ATE330593T1 (de) | 2006-07-15 |
KR20000022233A (ko) | 2000-04-25 |
HUP0003381A2 (hu) | 2001-05-28 |
ZA975773B (en) | 1998-12-28 |
CZ427798A3 (cs) | 1999-08-11 |
RU2185824C2 (ru) | 2002-07-27 |
IL127714A (en) | 2004-08-31 |
DE69736183T2 (de) | 2007-04-26 |
JP2002515875A (ja) | 2002-05-28 |
CN1224350A (zh) | 1999-07-28 |
AU3409697A (en) | 1998-01-21 |
CZ297342B6 (cs) | 2006-11-15 |
EP0932398B1 (en) | 2006-06-21 |
IL127714A0 (en) | 1999-10-28 |
ES2267144T3 (es) | 2007-03-01 |
SK180498A3 (en) | 2000-03-13 |
AU739363B2 (en) | 2001-10-11 |
DE69736183D1 (de) | 2006-08-03 |
WO1998000123A1 (en) | 1998-01-08 |
US5753693A (en) | 1998-05-19 |
AP1401A (en) | 2005-04-29 |
EP0932398A1 (en) | 1999-08-04 |
CA2258895A1 (en) | 1998-01-08 |
CA2258895C (en) | 2006-06-06 |
AP9801427A0 (en) | 1998-12-31 |
BR9712783A (pt) | 2000-10-24 |
NZ333565A (en) | 2000-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO986051D0 (no) | Antikonvulsive derivater for behandling av manisk-depressive mangler | |
NO986052D0 (no) | Antikonvulsive derivater for behandling av fedme | |
BR9507179A (pt) | Derivados de 3-aril-4-hidróxi-delta3-dihidrotiofena | |
NO986054D0 (no) | Antikonvulsive derivater for behandling av amyotrofisk lateral sklerose (AL | |
BR9611130A (pt) | Derivados de 3-aril-5-halógeno-pirona | |
BR9510256A (pt) | Derivados de ácido 3-aril-tetrônico | |
NO991955L (no) | FremgangsmÕte for behandling av hydrokarboner | |
FI972919A (fi) | Indolijohdannaisia jotka ovat käyttökelpoisia osteoporoosin hoidossa | |
NO982237L (no) | FremgangsmÕte for fremstilling av fenylimidazolidinderivater | |
PT829205E (pt) | Producao de condimento | |
FI973500A (fi) | 3-pyrrolidylideeni-2-oni-kefalosporiinien johdannaiset | |
NO996432D0 (no) | Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider | |
NO986053D0 (no) | Antikonvulsive derivater for behandling av psoriasis | |
NO993549D0 (no) | Imino-aza-antracyklinonderivater til behandling av amyloidosis | |
GB2305426B (en) | The purification of water | |
NO991148D0 (no) | Fremstilling av 1-butyl-4-piperidinyl-metylamin | |
NO972129D0 (no) | Fremgangsmåte for fremstilling av 1-halo-3-trialkylsilanyl-benzenderivater | |
NO962812D0 (no) | Fremgangsmåte for behandling av nervebetennelse | |
FI951047A (fi) | Menetelmä indolijohdannaisten valmistamiseksi | |
NO20003077L (no) | FremgangsmÕte for fremstilling av klorbenzooksazolen | |
BR9704770A (pt) | Derivados de 1-carba-(detia)-cefalosporina | |
NO964519D0 (no) | Fremgangsmåte for fremstilling av chitosanalkylderivater | |
NO994557D0 (no) | Fremgangsmaate for fremstilling av arylaminotriazolopyridiner | |
NO984190D0 (no) | Fremgangsmåte for behandling av insomnia | |
NO20002476L (no) | FremgangsmÕte for fremstilling av formylimidazoler |